Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers

Proteome Science

Volumn 9, Issue , 2011, Pages

  Monari, Emanuela ^a   Casali, Christian ^a   Cuoghi, Aurora ^a   Nesci, Jessica ^a   Bellei, Elisa ^a   Bergamini, Stefania ^a   Fantoni, Luca I ^a   Natali, Pamela ^a   Morandi, Uliano ^a   Tomasi, Aldo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN;

ADULT; AGED; ARTICLE; CLASSIFICATION ALGORITHM; CLINICAL ARTICLE; CONTROLLED STUDY; DECISION TREE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SERUM; STATISTICAL ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 80052850985     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-55     Document Type: Article

References (39)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907. 10.1158/1055-9965.EPI-10-0437, 20647400.
2. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. Jama 2007, 297:953-961. 10.1001/jama.297.9.953, 17341709.
3. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006, 6:961-967. 10.1038/nrc2011, 17093504.
4. De Bock M, de Seny D, Meuwis MA, Chapelle JP, Louis E, Malaise M, Merville MP, Fillet M. Challenges for Biomarker Discovery in Body Fluids Using SELDI-TOF-MS. J Biomed Biotechnol 2010,
5. Hutchens TW, Yip TT. New Desorption Strategies for the Mass-Spectrometric Analysis of Macromolecules. Rapid Commun Mass Sp 1993, 7:576-580.
6. Wright GL. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002, 2:549-563. 10.1586/14737159.2.6.549, 12465452.
7. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004, 23:34-44. 10.1002/mas.10066, 14625891.
8. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577. 10.1016/S0140-6736(02)07746-2, 11867112.
9. Moore LE, Fung ET, McGuire M, Rabkin CC, Molinaro A, Wang Z, Zhang F, Wang J, Yip C, Meng XY, Pfeiffer RM. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006, 15:1641-1646. 10.1158/1055-9965.EPI-05-0980, 16985025.
10. Clarke CH, Buckley JA, Fung ET. SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med 2005, 43:1314-1320. 10.1515/CCLM.2005.225, 16309366.
11. Leong S, Christopherson RI, Baxter RC. Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cell Physiol Biochem 2007, 20:579-590. 10.1159/000107541, 17762184.
12. Liu M, Li CF, Chen HS, Lin LQ, Zhang CP, Zhao JL, Liu Y, Zhang SJ, Jin JC, Wang L, Liu JR. Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls. Proteome Sci 2010, 8:16. 10.1186/1477-5956-8-16, 2862023, 20334691.
13. Adam BL, Qu YS, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng ZD, Wright GL. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002, 62:3609-3614.
14. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005, 51:102-112.
15. Bons JA, van Dieijen-Visser MP, Wodzig WK. Clinical proteomics in chronic inflammatory diseases: A review. Proteomics Clin Appl 2007, 1:1123-1133. 10.1002/prca.200700067, 21136762.
16. Hodgetts A, Levin M, Kroll JS, Langford PR. Biomarker discovery in infectious diseases using SELDI. Future Microbiol 2007, 2:35-49. 10.2217/17460913.2.1.35, 17661674.
17. Martinez-Pinna R, Martin-Ventura JL, Mas S, Blanco-Colio LM, Tunon J, Egido J. Proteomics in atherosclerosis. Curr Atheroscler Rep 2008, 10:209-215. 10.1007/s11883-008-0033-z, 18489848.
18. Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM. Applications of SELDI-MS technology in oncology. J Cell Mol Med 2008, 12:1535-1547. 10.1111/j.1582-4934.2008.00250.x, 18266982.
19. Yang S, Nan Y, Tian Y, Zhang W, Zhou B, Bu L, Huo S, Chen G, Yu J, Zheng S. Study of distinct protein profiles for early diagnosis of NSCLC using LCM and SELDI-TOF-MS. Med Oncol 2008, 25:380-386. 10.1007/s12032-008-9050-6, 18300004.
20. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003, 40:267-279. 10.1016/S0169-5002(03)00082-5, 12781425.
21. Au JS, Cho WC, Yip TT, Law SC. Proteomic approach to biomarker discovery in cancer tissue from lung adenocarcinoma among nonsmoking Chinese women in Hong Kong. Cancer Invest 2008, 26:128-135. 10.1080/07357900701788031, 18259942.
22. Bouamrani A, Ternier J, Ratel D, Benabid AL, Issartel JP, Brambilla E, Berger F. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin Chem 2006, 52:2103-2106. 10.1373/clinchem.2006.070979, 16990423.
23. Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005, 5:83. 10.1186/1471-2407-5-83, 1183195, 16029516.
24. Au JS, Cho WC, Yip TT, Yip C, Zhu H, Leung WW, Tsui PY, Kwok DL, Kwan SS, Cheng WW, et al. Deep proteome profiling of sera from never-smoked lung cancer patients. Biomed Pharmacother 2007, 61:570-577. 10.1016/j.biopha.2007.08.017, 17913442.
25. Dai S, Wang X, Liu L, Liu J, Wu S, Huang L, Xiao X, He D. Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum. Sci China C Life Sci 2007, 50:305-311. 10.1007/s11427-007-0053-x, 17609886.
26. Han M, Liu Q, Yu J, Zheng S. Detection and significance of serum protein markers of small-cell lung cancer. J Clin Lab Anal 2008, 22:131-137. 10.1002/jcla.20230, 18348318.
27. Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 2008, 31:133-139. 10.1097/COC.0b013e318145b98b, 18391596.
28. Yang Y, Zhao S, Fan Y, Zhao F, Liu Q, Hu W, Liu D, Fan K, Wang J. Detection and identification of potential biomarkers of non-small cell lung cancer. Technol Cancer Res Treat 2009, 8:455-466.
29. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867. 10.1074/mcp.R200007-MCP200, 12488461.
30. Righetti PG, Boschetti E, Lomas L, Citterio A. Protein Equalizer Technology: the quest for a "democratic proteome". Proteomics 2006, 6:3980-3992. 10.1002/pmic.200500904, 16800034.
31. Righetti PG, Boschetti E, Monsarrat B. The "Invisible Proteome": How to Capture the Low- abundance Proteins Via Combinatorial Ligand Libraries. Current proteomics 2007, 4:198-208.
32. Righetti PG, Boschetti E. The Proteominer and the Fortyniners: Searching for Gold Nuggets in the Proteomic Arena. Mass Spectrom Rev 2008, 27:596-608. 10.1002/mas.20178, 18481254.
33. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
34. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees 1984, 384. Belmont, CA: Chapman and Hall/CRC, 1.
35. Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, Ramirez J, Filella X. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 2008, 29:371-380. 10.1159/000181180, 19060513.
36. Bellei E, Bergamini S, Monari E, Fantoni LI, Cuoghi A, Ozben T, Tomasi A. High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids 2011, 40:145-156. 10.1007/s00726-010-0628-x, 20495836.
37. Hartwig S, Czibere A, Kotzka J, Passlack W, Haas R, Eckel J, Lehr S. Combinatorial hexapeptide ligand libraries (ProteoMiner): an innovative fractionation tool for differential quantitative clinical proteomics. Arch Physiol Biochem 2009, 115:155-160. 10.1080/13813450903154224, 19604127.
38. Sihlbom C, Kanmert I, Bahr H, Davidsson P. Evaluation of the combination of bead technology with SELDI-TOF-MS and 2-D DIGE for detection of plasma proteins. J Proteome Res 2008, 7:4191-4198. 10.1021/pr800340c, 18690747.
39. Roux-Dalvai F, Gonzalez de Peredo A, Simo C, Guerrier L, Bouyssie D, Zanella A, Citterio A, Burlet-Schiltz O, Boschetti E, Righetti PG, Monsarrat B. Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol Cell Proteomics 2008, 7:2254-2269. 10.1074/mcp.M800037-MCP200, 18614565.